Access to artesunate-amodiaquine, quinine and other anti-malarials: policy and markets in Burundi
Open Access
- 10 February 2011
- journal article
- Published by Springer Nature in Malaria Journal
- Vol. 10 (1) , 34
- https://doi.org/10.1186/1475-2875-10-34
Abstract
Malaria is the leading cause of morbidity and mortality in post-conflict Burundi. To counter the increasing challenge of anti-malarial drug resistance and improve highly effective treatment Burundi adopted artesunate-amodiaquine (AS-AQ) as first-line treatment for uncomplicated Plasmodium falciparum malaria and oral quinine as second-line treatment in its national treatment policy in 2003. Uptake of this policy in the public, private and non-governmental (NGO) retail market sectors of Burundi is relatively unknown. This study was conducted to evaluate access to national policy recommended anti-malarials.Keywords
This publication has 16 references indexed in Scilit:
- Universal access to malaria medicines: innovation in financing and deliveryThe Lancet, 2010
- Anti-malarial market and policy surveys in sub-Saharan AfricaMalaria Journal, 2010
- Retail sector distribution chains for malaria treatment in the developing world: a review of the literatureMalaria Journal, 2010
- Evaluating Different Dimensions of Programme Effectiveness for Private Medicine Retailer Malaria Control Interventions in KenyaPLOS ONE, 2010
- Quinine monotherapy for treating uncomplicated malaria in the era of artemisinin-based combination therapy: an appropriate public health policy?The Lancet Infectious Diseases, 2009
- Concentration and drug prices in the retail market for malaria treatment in rural TanzaniaHealth Economics, 2009
- Initial evidence of reduction of malaria cases and deaths in Rwanda and Ethiopia due to rapid scale-up of malaria prevention and treatmentMalaria Journal, 2009
- Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysisPublished by Elsevier ,2008
- Community coverage of an antimalarial combination of artesunate and amodiaquine in Makamba Province, Burundi, nine months after its introductionMalaria Journal, 2007
- Viewpoint: Management of malaria – working with the private sectorTropical Medicine & International Health, 1999